Ultragenyx Pharmaceutical
RARE
100 hedge funds and large institutions have $1.23B invested in Ultragenyx Pharmaceutical in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 23 reducing their positions, and 18 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 23
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
0% more funds holding
Funds holding: 100 → 100 (0)
14% less call options, than puts
Call options by funds: $342K | Put options by funds: $399K
18% less capital invested
Capital invested by funds: $1.5B → $1.23B (-$271M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$18.4M |
| 2 |
Millennium Management
New York
|
+$13.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$22.9M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$21.1M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.88M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$3.79M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.46M |
RARE Hedge Fund Activity: Q4 2014 in Review
100 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2014, worth a combined $1.23B — down 18% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RARE positions and 18 closed out — a net gain of 2 holders — while 39 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $18.4M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $22.9M.
- 100 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $1.23B of Ultragenyx Pharmaceutical stock for Q4 2014, down 18% quarter-over-quarter.
- 20 funds opened new Ultragenyx Pharmaceutical positions in Q4 2014 and 18 closed out, a net change of +2 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $18.4M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2014 was TPG Group Holdings (SBS) Advisors, an estimated $22.9M sold.
Based on aggregated 13F filings for Q4 2014.